Literature DB >> 8395657

A new topical treatment for resistant herpes simplex infections.

R Snoeck, G Andrei, E De Clercq, M Gerard, N Clumeck, G Tricot, C Sadzot-Delvaux.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 8395657     DOI： 10.1056/NEJM199309233291317

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

1.  Complex management of resistant oral herpes simplex virus infection following hematopoietic stem cell transplantation: potential role of topical cidofovir.

Authors:  Joel B Epstein; Sara Gharapetian; Ali R Rejali; Rachel Zabner; Michael Lill; Dimitrios Tzachanis
Journal:  Support Care Cancer       Date:  2016-05-10       Impact factor: 3.603

Review 2.  Current recommendations for the treatment of genital herpes.

Authors:  D T Leung; S L Sacks
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

3.  Antiviral activity of HPMPC (cidofovir) against orf virus infected lambs.

Authors:  A Scagliarini; C J McInnes; L Gallina; F Dal Pozzo; L Scagliarini; R Snoeck; S Prosperi; J Sales; J A Gilray; P F Nettleton
Journal:  Antiviral Res       Date:  2006-10-11       Impact factor: 5.970

4.  Susceptibilities of several drug-resistant herpes simplex virus type 1 strains to alternative antiviral compounds.

Authors:  G Andrei; R Snoeck; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

Review 5.  In search of a selective antiviral chemotherapy.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

6.  The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo.

Authors:  J Neyts; G Andrei; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

Review 7.  Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.

Authors:  Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

8.  In vivo antiherpesvirus activity of N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine.

Authors:  J Neyts; G Jähne; G Andrei; R Snoeck; I Winkler; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

9.  Biochemical basis for increased susceptibility to Cidofovir of herpes simplex viruses with altered or deficient thymidine kinase activity.

Authors:  D B Mendel; D B Barkhimer; M S Chen
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.